Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

PyPy, an alternative runtime for Python, uses a specially created JIT compiler to yield potentially massive speedups over CPython, the conventional Python runtime. But PyPy’s exemplary performance has ...

A manager assigns a team member to an unglamorous task. A senior colleague hands off a notoriously difficult client to a junior colleague. Someone must assume extra ...

The Chicago area isn't dealing with the remnants of a massive snowfall, but rather a much different type of winter weather: extreme cold. While accumulating snow is possible in the coming days, Friday ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Business Insider asked etiquette experts about the mistakes to avoid when attending a work event. Showing up dressed inappropriately and not greeting members of leadership are major faux pas. Hiding ...

Shae McCrystal has previously received funding from the Australian Research Council. Whether you’re an employee counting down the days until your break, or an employer trying to keep a business open ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...